Sustained Terminal Complement Inhibition on the Endothelium with Ravulizumab in Patients with Atypical Haemolytic Uraemic Syndrome.
- DOI
- 10.1159/000553556
- Published
- 2026 Jul 21
- Container
- Nephron
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1159/000553556,
title = {Sustained Terminal Complement Inhibition on the Endothelium with Ravulizumab in Patients with Atypical Haemolytic Uraemic Syndrome.},
author = {Gastoldi S and Bresin E and Pasini A and Nardini B and Paci Della Costanza O and Sciri R and Mele C and Benigni A and Remuzzi G and Noris M and Aiello S},
year = {2026},
journal = {Nephron},
doi = {10.1159/000553556},
url = {https://doi.org/10.1159/000553556}
}RIS
TY - JOUR TI - Sustained Terminal Complement Inhibition on the Endothelium with Ravulizumab in Patients with Atypical Haemolytic Uraemic Syndrome. AU - Gastoldi S AU - Bresin E AU - Pasini A AU - Nardini B AU - Paci Della Costanza O AU - Sciri R AU - Mele C AU - Benigni A AU - Remuzzi G AU - Noris M AU - Aiello S PY - 2026 JO - Nephron DO - 10.1159/000553556 UR - https://doi.org/10.1159/000553556 ER -
APA
S, G., E, B., A, P., B, N., O, P. D. C., R, S., C, M., A, B., G, R., M, N., & S, A. (2026). Sustained Terminal Complement Inhibition on the Endothelium with Ravulizumab in Patients with Atypical Haemolytic Uraemic Syndrome.. Nephron. https://doi.org/10.1159/000553556
Source records
- pubmed · retrieved 2026-09-27T12:16:11.868Z